Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28100804 | 1.00 | FOLH1 (0.47) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL43996 | 0.81 | FOLH1 (0.66) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL9875634 | 0.81 | FOLH1 (0.66) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL43995 | 0.81 | FOLH1 (0.66) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL27858773 | 0.78 | ALDH1A1 (0.45) | CA1CA2 | |
| Pyrrole SCHEMBL28847693 | 0.77 | FOLH1 (0.54) | FOLH1CPB2CA1CA2SLC15A2 | |
| 2-Pyrrolidone SCHEMBL28915581 | 0.72 | CPB2 (0.46) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL24141430 | 0.71 | FOLH1 (0.54) | FOLH1CPB2CA1CA2SLC15A2 | |
| SCHEMBL12572609 | 0.70 | FOLH1 (0.83) | FOLH1CPB2SLC6A5GSR | |
| SCHEMBL1006178 | 0.69 | FOLH1 (0.64) | FOLH1CPB2CA1CA2SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| EP-4436979-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-10-02 | — | — | EP | claimed |
| CN-118451091-A | Cleavable radioligands for targeting cell surface receptors and uses thereof | 辐联科技香港有限公司 | 2024-08-06 | — | — | CN | claimed |
| US-20240082404-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2024-03-14 | — | — | US | claimed |
| US-11857628-B2 | Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation | MOLECULAR TEMPLATES, INC. (US) | 2024-01-02 | — | — | US | claimed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | claimed |
| US-20220152213-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2022-05-19 | — | — | US | claimed |
| US-20210008208-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | MOLECULAR TEMPLATES, INC. (US) | 2021-01-14 | — | — | US | claimed |
| CN-110494443-A | The sub- polypeptide of shiga toxin A Effect of subunit, shiga toxin effect submounts and cell-targeting molecule for locus specificity conjugation | MOLECULAR TEMPLATES INC | 2019-11-22 | — | — | CN | claimed |
| EP-3551645-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | Molecular Templates, Inc. (US) | 2019-10-16 | — | — | EP | claimed |
| WO-2018106895-A1 | SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION | MOLECULAR TEMPLATES, INC. (US) | 2018-06-14 | — | — | WO | claimed |
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | disclosed |
| CN-122028940-A | PI4K inhibitor and application thereof | 清华大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-4735111-A1 | SINGLE-DOMAIN ANTIBODY FOR INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY | Université de Liège (BE) | 2026-05-06 | — | — | EP | disclosed |
| EP-2356092-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| EP-2356092-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010048582-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048582-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FOLH1 22/4885CPB2 471/4885CA1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.